ICER
Incremental cost-effectiveness ratio.
The headline number every HTA submission revolves around — the extra cost per QALY of your therapy versus the comparator. It's the price of the question every payer asks first.
The incremental cost-effectiveness ratio (ICER) is the extra cost per quality-adjusted life year (QALY) gained from your therapy versus its comparator. NICE benchmarks against £20,000–£30,000/QALY; severity modifiers and end-of-life criteria can stretch the threshold.
What kills an ICER isn't usually the model — it's the inputs. Comparator effectiveness, utility values, and time horizon assumptions are where committees push back.
Map the comparator, draft the clinical benefit narrative against G-BA expectations, and source every claim back to the trial publication, label or SmPC.
Build a NICE company evidence submission against the reference case: ITCs pre-checked, model inputs reproducible, every assumption traceable.
Pull every relevant comparator readout, precedent decision and methodological objection into one workspace.